{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:50:12Z","timestamp":1792601412606,"version":"4.5.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"vor","delay-in-days":21,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s00277-025-06507-7","type":"journal-article","created":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T07:41:46Z","timestamp":1753170106000},"page":"3745-3751","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Brentuximab vedotin plus CHP-like regimen for the first-line treatment of PTCL patients: a real-world single center study"],"prefix":"10.1007","volume":"104","author":[{"given":"Fangshu","family":"Guan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enfan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingsong","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,22]]},"reference":[{"issue":"10","key":"6507_CR1","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1182\/blood-2014-04-573089","volume":"124","author":"F Ellin","year":"2014","unstructured":"Ellin F, Landstrom J, Jerkeman M, Relander T (2014) Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry. Blood 124(10):1570\u20131577. https:\/\/doi.org\/10.1182\/blood-2014-04-573089","journal-title":"Blood"},{"issue":"12","key":"6507_CR2","doi-asserted-by":"publisher","first-page":"5496","DOI":"10.1182\/blood-2008-01-134270","volume":"111","author":"KJ Savage","year":"2008","unstructured":"Savage KJ, Harris NL et al (2008) ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK\u2009+\u2009ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the international peripheral T-Cell lymphoma project. Blood 111(12):5496\u20135504","journal-title":"Blood"},{"issue":"8","key":"6507_CR3","doi-asserted-by":"publisher","first-page":"e81","DOI":"10.3324\/haematol.2013.084913","volume":"98","author":"E Sabattini","year":"2013","unstructured":"Sabattini E, Pizzi M, Tabanelli V, Baldin P, Sacchetti CS, Agostinelli C et al (2013) CD30 expression in peripheral T-cell lymphomas. Haematologica 98(8):e81-82. https:\/\/doi.org\/10.3324\/haematol.2013.084913","journal-title":"Haematologica"},{"issue":"19","key":"6507_CR4","doi-asserted-by":"publisher","first-page":"2983","DOI":"10.1182\/blood-2014-07-584953","volume":"124","author":"C Bossard","year":"2014","unstructured":"Bossard C, Dobay MP, Parrens M, Lamant L, Leval LD (2014) Immunohistochemistry as a valuable tool to assess CD30 expression in peripheral T-cell lymphomas: high correlation with mRNA levels. Blood 124(19):2983\u20132986. https:\/\/doi.org\/10.1182\/blood-2014-07-584953","journal-title":"Blood"},{"issue":"20","key":"6507_CR5","doi-asserted-by":"publisher","first-page":"3095","DOI":"10.1182\/blood-2013-12-542142","volume":"123","author":"SM Horwitz","year":"2014","unstructured":"Horwitz SM, Advani RH, Bartlett NL, Jacobsen ED, Sharman JP, O\u2019Connor OA et al (2014) Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. Blood 123(20):3095\u20133100. https:\/\/doi.org\/10.1182\/blood-2013-12-542142","journal-title":"Blood"},{"issue":"28","key":"6507_CR6","doi-asserted-by":"publisher","first-page":"3137","DOI":"10.1200\/JCO.2013.54.2456","volume":"32","author":"MA Fanale","year":"2014","unstructured":"Fanale MA, Horwitz SM, Forero-Torres A, Bartlett NL, Advani RH, Pro B et al (2014) Brentuximab Vedotin in the front-line treatment of patients with CD30 + peripheral T-cell lymphomas: results of a phase I study. J Clin Oncol 32(28):3137\u20133143. https:\/\/doi.org\/10.1200\/JCO.2013.54.2456","journal-title":"J Clin Oncol"},{"issue":"20","key":"6507_CR7","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R et al (2016) The 2016 revision of the world health organization classification of lymphoid neoplasms. Blood 127(20):2375\u20132390. https:\/\/doi.org\/10.1182\/blood-2016-01-643569","journal-title":"Blood"},{"issue":"7","key":"6507_CR8","first-page":"29","volume":"43","author":"\u4e2d\u56fd\u6297\u764c\u534f\u4f1a\u6dcb\u5df4\u7624\u4e13\u4e1a\u59d4\u5458\u4f1a","year":"2021","unstructured":"\u4e2d\u56fd\u6297\u764c\u534f\u4f1a\u6dcb\u5df4\u7624\u4e13\u4e1a\u59d4\u5458\u4f1a, \u4e2d\u56fd\u533b\u5e08\u534f\u4f1a\u80bf\u7624\u533b\u5e08\u5206\u4f1a (2021) \u4e2d\u56fd\u533b\u7597\u4fdd\u5065\u56fd\u9645\u4ea4\u6d41\u4fc3\u8fdb\u4f1a\u80bf\u7624\u5185\u79d1\u5206\u4f1a. \u4e2d\u56fd\u6dcb\u5df4\u7624\u6cbb\u7597\u6307\u5357(2021\u5e74\u7248). \u4e2d\u534e\u80bf\u7624\u6742\u5fd7 43(7):29","journal-title":"\u4e2d\u534e\u80bf\u7624\u6742\u5fd7"},{"issue":"27","key":"6507_CR9","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E et al (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32(27):3059\u20133068. https:\/\/doi.org\/10.1200\/JCO.2013.54.8800","journal-title":"J Clin Oncol"},{"key":"6507_CR10","doi-asserted-by":"publisher","first-page":"6529","DOI":"10.1182\/blood-2024-202402","volume":"144","author":"Z Liu","year":"2024","unstructured":"Liu Z, Zheng Y, Liu X, Meng Q, Jiang X, Ji Q et al (2024) Real-world results of brentuximab vedotin containing regimens in CD30 positive lymphoma: a single-center retrospective study. Blood 144:6529\u20136529","journal-title":"Blood"},{"issue":"1","key":"6507_CR11","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1007\/s12325-021-01943-z","volume":"39","author":"X Feng","year":"2022","unstructured":"Feng X, Guo W, Wang Y, Li J, Zhao Y, Qu L et al (2022) The short-term efficacy and safety of brentuximab vedotin plus cyclophosphamide, epirubicin and prednisone in untreated PTCL: a real-world, retrospective study. Adv Ther 39(1):532\u2013543. https:\/\/doi.org\/10.1007\/s12325-021-01943-z","journal-title":"Adv Ther"},{"key":"6507_CR12","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyad068","author":"JM Burke","year":"2023","unstructured":"Burke JM, Liu N, Yu KS, Fanale MA, Surinach A, Flores C et al (2023) Retrospective analysis with propensity score matching of peripheral T-cell lymphoma treated frontline with brentuximab vedotin and chemotherapy. Oncologist. https:\/\/doi.org\/10.1093\/oncolo\/oyad068","journal-title":"Oncologist"},{"issue":"10168","key":"6507_CR13","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","volume":"393","author":"S Horwitz","year":"2019","unstructured":"Horwitz S, O\u2019Connor OA, Pro B, Illidge T, Fanale M, Advani R et al (2019) Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet 393(10168):229\u2013240. https:\/\/doi.org\/10.1016\/S0140-6736(18)32984-2","journal-title":"Lancet"},{"key":"6507_CR14","doi-asserted-by":"publisher","DOI":"10.5402\/2011\/623924","volume":"2011","author":"AN Abouyabis","year":"2011","unstructured":"Abouyabis AN, Shenoy PJ, Sinha R, Flowers CR, Lechowicz MJ (2011) A systematic review and meta-analysis of front-line anthracycline-based chemotherapy regimens for peripheral T-cell lymphoma. ISRN Hematol 2011. https:\/\/doi.org\/10.5402\/2011\/623924","journal-title":"ISRN Hematol"},{"issue":"5","key":"6507_CR15","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1182\/blood-2017-09-746420","volume":"131","author":"GA Abel","year":"2018","unstructured":"Abel GA, Klepin HD (2018) Frailty and the management of hematologic malignancies. Blood 131(5):515\u2013524. https:\/\/doi.org\/10.1182\/blood-2017-09-746420","journal-title":"Blood"},{"issue":"10","key":"6507_CR16","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1093\/oncolo\/oyac137","volume":"27","author":"D Jagadeesh","year":"2022","unstructured":"Jagadeesh D, Horwitz S, Bartlett NL, Kim Y, Jacobsen E, Duvic M et al (2022) Response to brentuximab vedotin by CD30 expression in Non-Hodgkin lymphoma. Oncologist 27(10):864\u2013873. https:\/\/doi.org\/10.1093\/oncolo\/oyac137","journal-title":"Oncologist"},{"issue":"24","key":"6507_CR17","doi-asserted-by":"publisher","first-page":"5588","DOI":"10.1182\/bloodadvances.2021005171","volume":"5","author":"M Rodriguez","year":"2021","unstructured":"Rodriguez M, Alonso-Alonso R, Tomas-Roca L, Rodriguez-Pinilla SM, Manso-Alonso R, Cereceda L et al (2021) Peripheral T-cell lymphoma: molecular profiling recognizes subclasses and identifies prognostic markers. Blood Adv 5(24):5588\u20135598. https:\/\/doi.org\/10.1182\/bloodadvances.2021005171","journal-title":"Blood Adv"},{"key":"6507_CR18","doi-asserted-by":"publisher","unstructured":"Reimer P, Rudiger T, Geissinger E, Weissinger F, Nerl C, Schmitz N et al (2009) Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J Clin Oncol 27(1):106\u2013113. https:\/\/doi.org\/10.1200\/JCO.2008.17.4870","DOI":"10.1200\/JCO.2008.17.4870"},{"issue":"25","key":"6507_CR19","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.1200\/JCO.2011.40.2719","volume":"30","author":"F d\u2019Amore","year":"2012","unstructured":"d\u2019Amore F, Relander T, Lauritzsen GF, Jantunen E, Hagberg H, Anderson H et al (2012) Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol 30(25):3093\u20133099. https:\/\/doi.org\/10.1200\/JCO.2011.40.2719","journal-title":"J Clin Oncol"},{"issue":"3","key":"6507_CR20","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1093\/annonc\/mdx787","volume":"29","author":"G Fossard","year":"2018","unstructured":"Fossard G, Broussais F, Coelho I, Bailly S, Nicolas-Virelizier E, Toussaint E et al (2018) Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers. Ann Oncol 29(3):715\u2013723. https:\/\/doi.org\/10.1093\/annonc\/mdx787","journal-title":"Ann Oncol"},{"issue":"11","key":"6507_CR21","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.3324\/haematol.2021.279426","volume":"107","author":"AM Garcia-Sancho","year":"2022","unstructured":"Garcia-Sancho AM, Bellei M, Lopez-Parra M, Gritti G, Cortes M, Novelli S et al (2022) Autologous stem-cell transplantation as consolidation of first-line chemotherapy in patients with peripheral T-cell lymphoma: a multicenter GELTAMO\/FIL study. Haematologica 107(11):2675\u20132684. https:\/\/doi.org\/10.3324\/haematol.2021.279426","journal-title":"Haematologica"},{"issue":"3","key":"6507_CR22","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1080\/17474086.2022.2042247","volume":"15","author":"Y Zhai","year":"2022","unstructured":"Zhai Y, Wang J, Jiang Y, Wu W, Lv Y, Xu H et al (2022) The efficiency of autologous stem cell transplantation as the first-line treatment for nodal peripheral T-cell lymphoma: results of a systematic review and meta-analysis. Expert Rev Hematol 15(3):265\u2013272. https:\/\/doi.org\/10.1080\/17474086.2022.2042247","journal-title":"Expert Rev Hematol"},{"key":"6507_CR23","doi-asserted-by":"publisher","unstructured":"Savage KJ, Horwitz SM, Advani R, Christensen JH, Domingo-Domenech E, Rossi G et al (2022) Role of stem cell transplant in CD30\u2009+\u2009PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2. Blood Adv 6(19):5550\u20135555. https:\/\/doi.org\/10.1182\/bloodadvances.2020003971","DOI":"10.1182\/bloodadvances.2020003971"},{"issue":"22","key":"6507_CR24","doi-asserted-by":"publisher","first-page":"3197","DOI":"10.1182\/blood-2014-06-537514","volume":"124","author":"SM Ansell","year":"2014","unstructured":"Ansell SM (2014) Brentuximab vedotin. Blood 124(22):3197\u20133200. https:\/\/doi.org\/10.1182\/blood-2014-06-537514","journal-title":"Blood"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06507-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06507-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06507-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T17:12:17Z","timestamp":1757265137000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06507-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":24,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["6507"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06507-7","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"18 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study protocol was approved by the Research Ethics Committee of the First Affiliated Hospital, College of Medicine, Zhejiang University, and written informed consent was waived. (IIT20241204A).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}